OA12927A - Novel triazole and oxazole compounds as transforming growth factor (TGF) inhibitors. - Google Patents
Novel triazole and oxazole compounds as transforming growth factor (TGF) inhibitors. Download PDFInfo
- Publication number
- OA12927A OA12927A OA1200500076A OA1200500076A OA12927A OA 12927 A OA12927 A OA 12927A OA 1200500076 A OA1200500076 A OA 1200500076A OA 1200500076 A OA1200500076 A OA 1200500076A OA 12927 A OA12927 A OA 12927A
- Authority
- OA
- OAPI
- Prior art keywords
- alkyl
- phenyl
- cio
- cycloalkyl
- heterocyclic
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US41207902P | 2002-09-18 | 2002-09-18 | |
| US48453503P | 2003-07-02 | 2003-07-02 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| OA12927A true OA12927A (en) | 2006-10-13 |
Family
ID=32033582
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| OA1200500076A OA12927A (en) | 2002-09-18 | 2003-09-08 | Novel triazole and oxazole compounds as transforming growth factor (TGF) inhibitors. |
Country Status (25)
| Country | Link |
|---|---|
| US (2) | US7053095B2 (pt) |
| EP (1) | EP1542685A1 (pt) |
| JP (1) | JP2006502236A (pt) |
| KR (1) | KR20050057393A (pt) |
| CN (1) | CN1681502A (pt) |
| AP (1) | AP2005003260A0 (pt) |
| AR (1) | AR041276A1 (pt) |
| AU (1) | AU2003260810A1 (pt) |
| BR (1) | BR0314577A (pt) |
| CA (1) | CA2497971A1 (pt) |
| CO (1) | CO5540390A2 (pt) |
| EA (1) | EA200500376A1 (pt) |
| EC (1) | ECSP055681A (pt) |
| HR (1) | HRP20050251A2 (pt) |
| IS (1) | IS7713A (pt) |
| MA (1) | MA27442A1 (pt) |
| MX (1) | MXPA05002982A (pt) |
| NO (1) | NO20051010L (pt) |
| OA (1) | OA12927A (pt) |
| PA (1) | PA8583401A1 (pt) |
| PE (1) | PE20050074A1 (pt) |
| PL (1) | PL375974A1 (pt) |
| TW (1) | TW200412346A (pt) |
| UY (1) | UY27981A1 (pt) |
| WO (1) | WO2004026307A1 (pt) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY140679A (en) | 2001-05-24 | 2010-01-15 | Avanir Pharmaceuticals | Inhibitors of macrohage migration inhibitory factor and methods for identifying the same |
| ES2335099T3 (es) * | 2002-09-18 | 2010-03-22 | Pfizer Products Inc. | Novedosos compuestos de pirazol como inhibidor del factor de crecimiento transformante (tgf). |
| ES2325687T3 (es) * | 2002-09-18 | 2009-09-14 | Pfizer Products Inc. | Compuestos de imidazol novedosos como inhibidores del factor de crecimiento transformante (tgf). |
| WO2004026863A1 (en) | 2002-09-18 | 2004-04-01 | Pfizer Products Inc. | Novel oxazole and thiazole compounds as transforming growth factor (tgf) inhibitors |
| PA8595001A1 (es) * | 2003-03-04 | 2004-09-28 | Pfizer Prod Inc | Nuevos compuestos heteroaromaticos condensados que son inhibidores del factor de crecimiento transforante (tgf) |
| JP4137174B2 (ja) * | 2005-02-23 | 2008-08-20 | 塩野義製薬株式会社 | チロシンキナーゼ阻害作用を有するキナゾリン誘導体 |
| US7781462B2 (en) * | 2005-07-25 | 2010-08-24 | Synta Pharmaceuticals Corp. | Compounds for the treatment of proliferative disorders |
| ZA200804496B (en) * | 2005-12-16 | 2009-09-30 | Alcon Inc | Control of intraocular pressure using ALK5 modulation agents |
| DE102005061840A1 (de) * | 2005-12-23 | 2007-06-28 | Merck Patent Gmbh | Triazolderivate |
| US9259426B2 (en) | 2006-07-20 | 2016-02-16 | Gilead Sciences, Inc. | 4,6-di- and 2,4,6-trisubstituted quinazoline derivatives useful for treating viral infections |
| WO2008009077A2 (en) * | 2006-07-20 | 2008-01-24 | Gilead Sciences, Inc. | 4,6-dl- and 2,4,6-trisubstituted quinazoline derivatives and pharmaceutical compositions useful for treating viral infections |
| US8871744B2 (en) | 2010-07-21 | 2014-10-28 | B & G Partyers, LLC | Compounds and methods for selectively targeting tumor-associated mucins |
| US9782452B2 (en) | 2011-11-22 | 2017-10-10 | Cornell University | Methods for stimulating hematopoietic recovery by inhibiting TGFβ signaling |
| JP6449772B2 (ja) | 2012-10-05 | 2019-01-09 | カドモン コーポレイション，リミティド ライアビリティ カンパニー | ヒト抗ｖｅｇｆｒ２／ｋｄｒ抗体 |
| KR102168088B1 (ko) | 2013-03-14 | 2020-10-20 | 더 브리검 앤드 우먼즈 하스피털, 인크. | 상피 줄기 세포 확장 및 배양을 위한 조성물 및 방법 |
| US10030004B2 (en) | 2014-01-01 | 2018-07-24 | Medivation Technologies Llc | Compounds and methods of use |
| IL299964A (en) | 2014-09-03 | 2023-03-01 | Massachusetts Inst Technology | Preparations, systems and methods for producing hair cells in the inner ear to treat hearing loss |
| EP3097102B1 (en) | 2015-03-04 | 2017-10-18 | Gilead Sciences, Inc. | Toll-like receptor modulating 4,6-diamino-pyrido[3,2-d]pyrimidine compounds |
| CA3010610A1 (en) | 2016-01-08 | 2017-07-13 | The Brigham And Women's Hospital, Inc. | Production of differentiated enteroendocrine cells and insulin producing cells |
| US11260130B2 (en) | 2016-03-02 | 2022-03-01 | Frequency Therapeutics, Inc. | Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using a GSK3 inhibitor: IV |
| US10213511B2 (en) | 2016-03-02 | 2019-02-26 | Frequency Therapeutics, Inc. | Thermoreversible compositions for administration of therapeutic agents |
| US10201540B2 (en) | 2016-03-02 | 2019-02-12 | Frequency Therapeutics, Inc. | Solubilized compositions for controlled proliferation of stem cells / generating inner ear hair cells using GSK3 inhibitors: I |
| US10640499B2 (en) | 2016-09-02 | 2020-05-05 | Gilead Sciences, Inc. | Toll like receptor modulator compounds |
| EP3507276B1 (en) | 2016-09-02 | 2021-11-03 | Gilead Sciences, Inc. | Toll like receptor modulator compounds |
| CA3048220A1 (en) | 2016-12-30 | 2018-07-05 | Frequency Therapeutics, Inc. | 1h-pyrrole-2,5-dione compounds and methods of using them to induce self-renewal of stem/progenitor supporting cells |
| US11866427B2 (en) | 2018-03-20 | 2024-01-09 | Icahn School Of Medicine At Mount Sinai | Kinase inhibitor compounds and compositions and methods of use |
| CN112867724B (zh) | 2018-07-23 | 2024-06-04 | 熙源安健医药(北京)有限公司 | 二膦酸盐药物缀合物 |
| US11617745B2 (en) | 2018-08-17 | 2023-04-04 | Frequency Therapeutics, Inc. | Compositions and methods for generating hair cells by downregulating FOXO |
| EP3837352A1 (en) | 2018-08-17 | 2021-06-23 | Frequency Therapeutics, Inc. | Compositions and methods for generating hair cells by upregulating jag-1 |
| US20220162182A1 (en) | 2018-12-31 | 2022-05-26 | Icahn School Of Medicine At Mount Sinai | Kinase inhibitor compounds and compositions and methods of use |
| TWI751516B (zh) | 2019-04-17 | 2022-01-01 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
| TWI751517B (zh) | 2019-04-17 | 2022-01-01 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
| TW202115056A (zh) | 2019-06-28 | 2021-04-16 | 美商基利科學股份有限公司 | 類鐸受體調節劑化合物的製備方法 |
| CN112694477B (zh) * | 2019-10-22 | 2024-02-06 | 四川科伦博泰生物医药股份有限公司 | 吡唑并环类化合物，包含其的药物组合物，其制备方法及其用途 |
Family Cites Families (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS6058981A (ja) * | 1983-09-09 | 1985-04-05 | Takeda Chem Ind Ltd | ５−ピリジル−１，３−チアゾ−ル誘導体，その製造法およびそれを含んでなる医薬組成物 |
| JPS6025142A (ja) | 1983-07-21 | 1985-02-07 | Matsushita Electric Ind Co Ltd | 表示装置の電極製造方法 |
| DE3486009T2 (de) * | 1983-09-09 | 1993-04-15 | Takeda Chemical Industries Ltd | 5-pyridyl-1,3-thiazol-derivate, ihre herstellung und anwendung. |
| GB9201692D0 (en) * | 1992-01-27 | 1992-03-11 | Smithkline Beecham Intercredit | Compounds |
| US6514977B1 (en) | 1997-05-22 | 2003-02-04 | G.D. Searle & Company | Substituted pyrazoles as p38 kinase inhibitors |
| RU2249591C2 (ru) | 1997-05-22 | 2005-04-10 | Дж.Д. Серл Энд Ко. | 3(5)-гетероарилзамещенные пиразолы в качестве ингибиторов киназы p38 |
| EP1019394A1 (en) | 1997-05-22 | 2000-07-19 | G.D. Searle & Co. | PYRAZOLE DERIVATIVES AS p38 KINASE INHIBITORS |
| US6436966B1 (en) * | 1997-10-27 | 2002-08-20 | Takeda Chemical Ind., Ltd. | Adenosine A3 receptor antagonists |
| JP2002541253A (ja) | 1999-04-09 | 2002-12-03 | スミスクライン・ビーチャム・コーポレイション | トリアリールイミダゾール |
| JP2000302680A (ja) * | 1999-04-23 | 2000-10-31 | Takeda Chem Ind Ltd | 脳保護剤 |
| AU6471300A (en) * | 1999-08-06 | 2001-03-05 | Takeda Chemical Industries Ltd. | P38map kinase inhibitors |
| AR029803A1 (es) | 2000-02-21 | 2003-07-16 | Smithkline Beecham Plc | Imidazoles sustituidos con piridilo y composiciones farmaceuticas que las comprenden |
| GB0007405D0 (en) | 2000-03-27 | 2000-05-17 | Smithkline Beecham Corp | Compounds |
| PE20020506A1 (es) | 2000-08-22 | 2002-07-09 | Glaxo Group Ltd | Derivados de pirazol fusionados como inhibidores de la proteina cinasa |
| GB0027987D0 (en) | 2000-11-16 | 2001-01-03 | Smithkline Beecham Plc | Compounds |
| AU2002225730A1 (en) | 2000-11-16 | 2002-05-27 | Smith Kline Beecham Corporation | Compounds |
| WO2002051442A1 (fr) * | 2000-12-26 | 2002-07-04 | Takeda Chemical Industries, Ltd. | Co-prescriptions |
| GB0100762D0 (en) | 2001-01-11 | 2001-02-21 | Smithkline Beecham Plc | Novel use |
| GB0102665D0 (en) * | 2001-02-02 | 2001-03-21 | Glaxo Group Ltd | Compounds |
| GB0102668D0 (en) * | 2001-02-02 | 2001-03-21 | Glaxo Group Ltd | Compounds |
| EP1357116A4 (en) * | 2001-02-02 | 2005-06-01 | Yamanouchi Pharma Co Ltd | 2-ACYLAMINOTHIAZOLE DERIVATIVE OR SALT THEREOF |
| WO2002062787A1 (en) | 2001-02-02 | 2002-08-15 | Glaxo Group Limited | Pyrazoles as tgf inhibitors |
| GB0102673D0 (en) * | 2001-02-02 | 2001-03-21 | Glaxo Group Ltd | Compounds |
| GB0102672D0 (en) | 2001-02-02 | 2001-03-21 | Glaxo Group Ltd | Compounds |
| US20040087623A1 (en) | 2001-02-02 | 2004-05-06 | Gellibert Francoise Jeanne | Pyrazole derivatives against tgf overexpression |
| WO2002100433A1 (en) * | 2001-06-11 | 2002-12-19 | Takeda Chemical Industries, Ltd. | Medicinal compositions |
| AR039241A1 (es) | 2002-04-04 | 2005-02-16 | Biogen Inc | Heteroarilos trisustituidos y metodos para su produccion y uso de los mismos |
| AR040726A1 (es) | 2002-07-31 | 2005-04-20 | Smithkline Beecham Corp | Compuesto de 2- fenilpiridin-4-il-heterociclico, composicion farmaceutica que lo comprende y su uso para la fabricacion de un medicamento |
| GB0217780D0 (en) | 2002-07-31 | 2002-09-11 | Glaxo Group Ltd | Compounds |
-
2003
- 2003-09-08 JP JP2004568900A patent/JP2006502236A/ja not_active Abandoned
- 2003-09-08 CA CA002497971A patent/CA2497971A1/en not_active Abandoned
- 2003-09-08 PL PL03375974A patent/PL375974A1/xx not_active Application Discontinuation
- 2003-09-08 MX MXPA05002982A patent/MXPA05002982A/es unknown
- 2003-09-08 AU AU2003260810A patent/AU2003260810A1/en not_active Abandoned
- 2003-09-08 OA OA1200500076A patent/OA12927A/en unknown
- 2003-09-08 KR KR1020057004575A patent/KR20050057393A/ko not_active Application Discontinuation
- 2003-09-08 CN CNA038221594A patent/CN1681502A/zh active Pending
- 2003-09-08 EP EP03797428A patent/EP1542685A1/en not_active Withdrawn
- 2003-09-08 WO PCT/IB2003/003825 patent/WO2004026307A1/en active Application Filing
- 2003-09-08 BR BR0314577-8A patent/BR0314577A/pt not_active IP Right Cessation
- 2003-09-08 EA EA200500376A patent/EA200500376A1/ru unknown
- 2003-09-08 AP AP2005003260A patent/AP2005003260A0/xx unknown
- 2003-09-16 PE PE2003000947A patent/PE20050074A1/es not_active Application Discontinuation
- 2003-09-16 UY UY27981A patent/UY27981A1/es not_active Application Discontinuation
- 2003-09-16 AR ARP030103360A patent/AR041276A1/es unknown
- 2003-09-17 US US10/667,183 patent/US7053095B2/en not_active Expired - Fee Related
- 2003-09-17 TW TW092125634A patent/TW200412346A/zh unknown
- 2003-09-17 PA PA20038583401A patent/PA8583401A1/es unknown
-
2005
- 2005-02-24 NO NO20051010A patent/NO20051010L/no unknown
- 2005-02-24 IS IS7713A patent/IS7713A/is unknown
- 2005-03-16 CO CO05024528A patent/CO5540390A2/es not_active Application Discontinuation
- 2005-03-17 HR HR20050251A patent/HRP20050251A2/hr not_active Application Discontinuation
- 2005-03-17 EC EC2005005681A patent/ECSP055681A/es unknown
- 2005-03-18 MA MA28156A patent/MA27442A1/fr unknown
-
2006
- 2006-02-07 US US11/349,481 patent/US20060128761A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP1542685A1 (en) | 2005-06-22 |
| CA2497971A1 (en) | 2004-04-01 |
| MXPA05002982A (es) | 2005-06-22 |
| IS7713A (is) | 2005-02-24 |
| US7053095B2 (en) | 2006-05-30 |
| AP2005003260A0 (en) | 2005-03-31 |
| PA8583401A1 (es) | 2004-04-23 |
| AR041276A1 (es) | 2005-05-11 |
| EA200500376A1 (ru) | 2005-08-25 |
| CO5540390A2 (es) | 2005-07-29 |
| HRP20050251A2 (en) | 2005-10-31 |
| TW200412346A (en) | 2004-07-16 |
| US20040110798A1 (en) | 2004-06-10 |
| WO2004026307A1 (en) | 2004-04-01 |
| BR0314577A (pt) | 2005-08-09 |
| PE20050074A1 (es) | 2005-03-21 |
| CN1681502A (zh) | 2005-10-12 |
| MA27442A1 (fr) | 2005-07-01 |
| PL375974A1 (en) | 2005-12-12 |
| NO20051010L (no) | 2005-05-31 |
| KR20050057393A (ko) | 2005-06-16 |
| ECSP055681A (es) | 2005-05-30 |
| AU2003260810A1 (en) | 2004-04-08 |
| JP2006502236A (ja) | 2006-01-19 |
| US20060128761A1 (en) | 2006-06-15 |
| UY27981A1 (es) | 2004-04-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| OA12927A (en) | Novel triazole and oxazole compounds as transforming growth factor (TGF) inhibitors. | |
| US7199123B2 (en) | Pyrazine compounds as transforming growth factor (TGF) compounds | |
| CA2496295C (en) | Novels pyrazole compounds as transforming growth factor (tgf) inhibitors | |
| EP1542990B1 (en) | Novel imidazole compounds as transforming growth factor (tgf) inhibitors | |
| US7030125B2 (en) | Isothiazole and isoxazole compounds as transforming growth factor (TGF) inhibitors | |
| OA12926A (en) | Novel oxazole and thiazole compounds as transforming growth factor (TGF) inhibitors. | |
| ZA200502277B (en) | Novel isothiazole and isoxazole compounds as transforming growth factor (TGF) inhibitors. |